期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

不同剂量FLAG方案治疗难治性急性髓细胞白血病的临床观察 被引量：6

原文传递
导出
摘要 目的研究不同剂量FLAG方案治疗难治性急性髓细胞白血病(AML)的疗效。方法将华中科技大学同济医学院附属协和医院血液科2003-07～2005-02收治的18例成人难治性AML分为两组。标准剂量阿糖胞苷(Ara-C)组13例患者应用:氟达拉滨(Flu)30mg/(m2·d)30min内静滴,连用5d;Ara-C500mg/(m2·d)或1000mg/(m2·d),连用5d。如WBC<2×109/L,则应用粒细胞集落刺激因子300μg;降低剂量Ara-C组5例患者Ara-C剂量100mg/(m2·d),连用5d,其余药物和标准剂量组相同。结果标准剂量Ara-C组的1个疗程完全缓解(CR)率明显较降低剂量Ara-C组高(P<0.01)。而感染等并发症两组间差异无统计学意义(P>0.05)。结论减量Ara-C治疗AML并未显著减轻化疗的感染、骨髓抑制等并发症,但CR率明显较应用标准剂量治疗时低。
作者 黎纬明 邹萍 张敏 何静 陈智超
机构地区 华中科技大学同济医学院附属协和医院血液科
出处 《中国实用内科杂志》 CAS CSCD 北大核心 2006年第1期43-44,共2页 Chinese Journal of Practical Internal Medicine
关键词 氟达拉滨 阿糖胞苷 急性髓细胞白血病 难治性
分类号 R5 [医药卫生—内科学]
  • 相关文献

参考文献6

  • 1Jackson GH. Use of fludarabine in the treatment of acute myeloid leukemia [J]. Hematol J, 2004, 5 (suppl 1):62-67.
  • 2Belhabri A, Thomas X, Wattel E, et al. All trans retinoic acid in combination with intermediate - dose cytarabine and idarubicin in patients with relapsed or refractory non promyelocytic acute myeloid leukemia: a phase Ⅱ randomized trial [ J ]. Hematol J,2002, 3 (1): 49-55.
  • 3Gandhi V, Estey E, Keating M J, et al. Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy [J]. J Clin Oncol, 1993, 11 (1) : 116-124.
  • 4Yamada K, Furusawa S, Saito K, et al. Concurrent use of granulocyte colony - stimulating factor with low - dose cytosine arabinoside and aclarubicin for previously treated acute myelogenous leukemia: apilot study [J]. Leukemia, 1995, 9 (1): 10-14.
  • 5孟凡义,杨龙江,徐兵,刘晓力,郑维扬,张钰,黄芬,孙竞,刘启发.改良FLAG方案治疗33例难治复发性急性白血病的初步分析[J].癌症,2003,22(12):1330-1333. 被引量：15
  • 6翁建宇,杜欣,陆泽生,黄梓伦,林伟.减量FLAG方案治疗难治性急性白血病[J].实用医学杂志,2004,20(8):944-945. 被引量：7

二级参考文献18

  • 1[1]Belhabri A, Thomas X, Wattel E, et al. All trans retinoic acid in combination with intermediate-dose cytarabine and idarubicin in patients with relapsed or refractory non promyelocytic acute myeloid leukemia: a phase Ⅱ randomized trial [J] . Hematol J,2002,3(1):49 -55.
  • 2[2]Carella AM, Carlier P, Pungolino E, et al. Idarubicin in combination with intermediate -dose cytarabine and VP-16 in the treatment of refractory or rapidly relapsed patients with acute myeloid leukemia. The GIMEMA Cooperative Group [J] .Leukemia, 1993, 7 (2): 196 - 199.
  • 3[3]Ozkaynak MF, Avramis Ⅵ, Carcich S, et al. Pharmacology of cytarabine given as a continuous infusion followed by mitoxantrone with and without amsacrine/etoposide as reinduction chemotherapy for relapsed or refractory pediatric acute myeloid leukemia [J].Med Pediatr Oncol, 1998, 31 (6): 475 -482.
  • 4[4]Harousseau JL, Milpied N, Briere J, et al. Mitoxantrone and intermediate -dose cytarabine in relapsed or refractory acute myeloblastic leukemia [J]. Nouv Rev Fr Hematol, 1990, 32(4):227 - 230.
  • 5[5]Weiss L, Abdul-Hai A, Or R, et al. Fludarabine in combination with cyclophosphamide decreases incidence of GVHD and maintains effective graft-versus-leukemia effect after allogeneic stem cell transplantation in murine lymphocytic leukemia [J].Bone Marrow Transplant, 2003, 31 ( 1 ): 11 - 15.
  • 6[6]McCarthy AJ, Pitcher LA, Hann IM, et al. FLAG(fludarabine,high-dose cytarabine, and G-CSF) for refractory and high-risk relapsed acute leukemia in children [J]. Med Pediatr Oncol, 1999,32(6):411 -415.
  • 7[7]Montillo M, Mirto S, Petti MC, et al. Fludarabine, cytarabine, and G-CSF (FLAG) for the treatment of poor risk acute myeloid leukemia [J]. Am J Hematol, 1998, 58(2): 105 - 109.
  • 8[8]Ferrara F, Palmieri S, Pocali B, et al. De novo acute myeloid leukemia with multilineage dysplasia: treatment results and prognostic evaluation from a series of 44 patients treated with fludarabine, cytarabine and G-CSF (FLAG) [J]. Eur J Haematol,2002, 68(4): 203 - 209.
  • 9[9]Hanel M, Friedrichsen K, Hanel A, et al. Mito-flag as salvage therapy for relapsed and refractory acute myeloid leukemia [J].Onkologie, 2001, 24(4): 356 - 360.
  • 10[10]Jackson G, Taylor P, Smith GM, et al. A multicentre, open,non-comparative phase Ⅱ study of a combination of fludarabine phosphate, cytarabine and granulocyte colony-stimulating factor in relapsed and refractory acute myeloid leukaemia and de novo refractory anaemia with excess of blasts in transformation [J]. Br J Haematol, 2001, 112(1): 127 - 137.

共引文献17

同被引文献26

引证文献6

二级引证文献19

中国实用内科杂志
2006年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部